Title: TREATMENT OF STAPHYLOCOCCUS INFECTIONS USING TRANSGENIC EXPRESSION OF A MODIFIED LYSOSTAPHIN GENE

Abstract: The present invention relates to an improved approach for the treatment of microbial infections in mammals. Specifically, the invention provides methods and reagents of expressing in mammalian cells, proteins having anti-microbial activity. The invention provides both genes, which have been modified to allow expression and preferably secretion of active protein in desired mammalian cells or tissues, and methods of introducing such modified genes into desired mammalian cells and/or tissues. Most specifically, genes encoding anti-staphylococcal proteins are delivered to mammalian cells and/or tissues by methods of gene delivery, including gene therapy and the production of transgenic animals, for the treatment of mastitis in ruminant animals.
Priority Information

This application claims priority to U.S. Application No, 10/087,667 filed February 28, 2002 the entire contents of which are incorporated herein by reference.

Background of the Invention

Bovine staphylococcal mastitis is a frequent problem for the dairy industry, and leads to estimated annual economic losses of $184 per cow per year. This corresponds to a U.S. total of $1.7 billion per year for milk producers and milk processors. These losses arise from reduced milk yield, reduced compositional quality, lower product quality, and increased veterinary costs.


Although sterilization techniques and the use of antibiotics have had a positive impact on dairy animal health and milk production, the prognosis for the elimination of *S. aureus* infection is poor, with often less than a 15% cure rate. This problem may be attributable to incomplete penetration of the antibiotics and/or sequestration of the bacteria within the host cells, leading to relapse of the infection once treatment has ended (Craven and Anderson, *supra*). The widespread use of antibiotics in dairy animals is also of great concern to the consumer. One problem is accidental exposure of the consumer to the antibiotic drug that can induce a strong immune response.
resulting in anaphylaxis. There is also a concern that the overuse of antibiotics selects
for microorganisms that are resistant to the antibiotic. Many *S. aureus* strains have
already acquired resistance to commonly used antibiotics such as ampicillin and
penicillin. Such prevalent problems have made it necessary to discard milk for a
period of up to 96 hours after antibiotic treatment of an animal, resulting in an
enormous waste of milk product and cost to milk producers.

There is a need for the development of an improved approach to treating
mastitis infections.

**Summary of the Invention**

The present invention provides an improved approach for the treatment of
microbial infections in mammals. In particular, the invention provides methods and
reagents for expressing in mammalian cells microbial proteins that have anti-microbial,
particularly anti-staphylococcal, activity. The invention provides both altered genes,
in which the naturally-occurring microbial sequences have been engineered to allow
expression of active protein in desired mammalian cells or tissues, and methods of
introducing such altered genes into desired mammalian cells and/or tissues. In certain
preferred embodiments, an altered gene is modified in such a manner that the protein it
encodes is not only produced in mammalian cells but is secreted from those cells, so
that a local concentration of anti-staphylococcal protein is created outside of the cells.
Most preferably, such cells either are, or are in the vicinity of, cells that are targeted by
infectious microbes *S. aureus* for attachment and penetration. In alternative preferred
embodiments, an altered gene is prepared so that the anti-microbial protein is
expressed within cells that are sensitive to intracellular infection.

The teachings of the present invention are particularly applicable to treatment
of staphylococcal mastitis infections in ruminants, such as cows, goats, and sheep;
most particularly in cows. In certain preferred embodiments of the invention, the
altered gene is delivered to mammary tissue in a form and through a mechanism that
allows transient transfection of certain cells, preferably localized within the lining of
the teat. In alternative preferred embodiments, the altered gene is delivered through the
production of a transgenic animal. Any of a variety of anti-microbial agents may be employed according to the present invention, but one particularly preferred agent is lysostaphin. In preferred embodiments the natural lysostaphin gene is altered to contain one or more of a mammalian promoter, transcriptional regulatory sequence, transcriptional termination signal and/or polyA site, splicing sequences, and translation initiation sequences. Preferred altered genes also include sequences that mediate lysostaphin export from the mammalian cells in which the protein is expressed. Particularly preferred altered genes contain sequence modifications that disrupt one or more post-translational processing events that would otherwise occur upon expression of the lysostaphin protein in the mammalian cells.

**Description of the Drawing**

Figure 1 is a schematic representation of the preprolysostaphin polypeptide.

Figure 2 is a representation of modifications of the lysostaphin gene for eukaryotic expression.

Figure 3 is an experiment demonstrating lysis of *S. aureus* by bioactive lysostaphin produced by COS-7 cells transfected with pCMV-Lys. Top row, lysostaphin standards at concentrations of 10, 33, 100, and 333 ug/ml; middle row, blank, 1X, 2X, 4X cell extract; bottom row, blank, 1X, 2X, 4X conditioned media.

Figure 4 is a Western blot of conditioned media samples treated with or without N-glycosidase-F. Molecular size standards are shown on the left. Samples in lanes 1, 2, and 3 were untreated, and contain 20 ul of media from COS-7 cells transfected with: pCMV-hGH control, spiked with 1 ug/ml lysostaphin (lane 1), pCMV-hGH control (lane 2), pCMV-hGH-Lys (lane 3). Samples in lanes 4 and 6 were incubated with deglycosylation buffers, no enzyme, for 16 hours, 37°. Sample in lane 5 was incubated with deglycosylation buffers, and enzyme, for 16 hours, 37°. Lanes contain 20 ul of media from COS-7 cells transfected with p CMV-hGH (lanes 4), pCMV-hGH-Lys (lanes 5, 6).

Figure 5 is a bacterial plate assay for detection of lysis of *S. aureus* (M60) by media or cell extracts from transfected COS-7 cells. Media and cell extracts were
obtained 48 hours post transfection with (1) pCMV-Lys, (2) pCMV-hGH-Lys, (3) pCMV-hGH-Lys-$\Delta$Gly1-$\Delta$Gly2, (4) pCMV-hGH genomic as a control. Conditioned media or cell extracts were lyophilized and resuspended with one third the original volume of H$_2$O. Top row: lysostaphin standards at concentrations of 11, 33, 100 or 300 ng/ml in media. Second row: conditioned media, Third row: cell extracts. Bottom row: lysostaphin standards that were diluted 1:3 in media, lyophilized, and resuspended with one third the original volume of H$_2$O.

Figure 6 represents Western blot analysis of lysostaphin expressed in transfected COS-7 cells. Molecular size standards are shown on the left. Lanes contain 50 $\mu$l cell extract (CE), or media (M), respectively, from cells transfected with: pCMVB-hGH as control (lanes 1, 2), pCMV-hGH-Lys (lanes 3, 4), pCMV-hGH-Lys-$\Delta$Gly2 (lanes 5, 6), pCMV-hGH with standard lysostaphin protein added to 1 $\mu$g/ml (lanes 7, 8), Ad-preprolyostaphin (lanes 10, 11). Lane 9 (*) contained culture media and Ad-preprolyostaphin as used for infection.

Figure 7 shows tissue fragments, tissue section and cultured cells, exposed to the X-gal reagent for visualization of $\beta$-galactosidase activity (panel A-D). (A) Teat tissue, (B) adjacent mammary tissue, (C) sections of teat tissue (40x), (D) primary culture of mammary tissue from one goat mammary gland transfected with LacZ-containing adenovirus (Av1Lac4) by intramammary infusion. The contralateral gland was infused with vehicle and blue staining was not observed (lower tissue pieces panel A and B). (E) Bovine mammary epithelial cell line (BME-UV) following transfection with AvLacZ4. (F) Green fluorescent protein in COS-7 cells transfected with the GFP gene.

Figure 8 depicts lysis of S. aureus by bioactive lysostaphin produced by 293 cells infected with Ad-hGH-Lys-$\Delta$GLY1-$\Delta$GLY2. Lysostaphin standards were prepared in media. The concentrations were 3 ng/ul, 30 ng/ul and 100 ng/ul. Samples (60 ul) or standards (15 ul) were added to a LB agar plate freshly streaked with S. aureus. Results were evaluated following a 12 hour incubation at 37$^0$. Top row, from left to right: lysostaphin standards at concentrations of 3, 100, 30 ng/ul; middle row, from left to right: cell culture media of 293 cells infected by Ad-hGH-Lys- $\Delta$GLY1-
ΔGLY2 isolates #4 and #6, and by 293 cells infected with parent virus Addl 327. Bottom row, from left to right: fresh cell culture media, cell culture media of 293 cells infected by Addl 327, and cell culture media of uninfected 293 cells.

Figure 9 shows a Western blot of lysostaphin in milk from transgenic mice containing the BLG-Sec-Lys-Gln2 construct. Lane 1 contains 10 μl of lysostaphin standard (Sigma 1μg/μl) in PBS - 1% BSA. Lanes 2-4 contain milk samples from three different transgenic mice (10μl milk diluted 1:10 in PBS - 1% BSA).

Lysostaphin was not detected in non-transgenic mouse milk.

Figure 10 shows a bacterial plate assay for lysostaphin bioactivity in mouse milk. Milk samples or lysostaphin standards (15 μl) were spotted onto a freshly plated lawn of S. aureus and lytic zones were observed after overnight incubation. Top row, left to right: bacterially derived lysostaphin (Sigma 500, 250, 125, 62 ng/ml in PBS-1% BSA) middle row, left to right: skim milk from a BLG-Sec-Lys-Gln2 transgenic mouse (#16755) diluted 1:200, 1:400, 1:800 or 1:1600 in PBS - 1% BSA. Bottom row, left to right: skim milk from a non-transgenic mouse diluted 1:200, 1:400, 1:800 1:1600 in PBS - 1% BSA.

Figure 11 depicts the entire DNA sequence of the lysostaphin gene cloned by Recsei et al., Proc. Natl. Acad. Sci. U.S.A., 84:1127-1131, 1987 (A), and the DNA sequence encoding the mature lysostaphin protein (Recsei et al., supra) (B).

Figure 12 depicts the preprolysostaphin amino acid sequence encoded by the lysostaphin gene cloned by Recsei et al., supra.

Figure 13 depicts the DNA coding sequence of the mature lysostaphin protein of the present invention containing 12 amino acid substitutions, as compared to the Recsei et al. (supra) sequence. The modified sequence encodes a 246 amino acid protein in which all but 2 amino acids are identical to the protein encoded by the Recsei et al. (supra) sequence.

Figure 14 depicts the DNA sequence of the β-lytic protease gene (Li et al., J. Bacteriol., 172:6506-6511, 1990) (A), and the β-lytic protease amino acid sequence encoded by the β-lytic protease gene (B).
Figure 15 depicts the lysostaphin DNA sequence cloned by Heinrich et al., 
*Mol. Gen. Genetic.*, 209:563-569, 1987) (A), and the amino acid sequence encoded by 
that gene (B).

Figure 16 depicts the DNA sequence of the lysostaphin gene cloned by Thumm 
and Gotz et al., *(Molecular Microbiology, 23:1251-1265, 1997).* The sequence 
presented encodes three bacterial genes. Lysostaphin is encoded by nucleotides 725-
2018 of the DNA sequence.

Figure 17 depicts the amino acid sequence of the lysostaphin gene cloned by 
(Thumm and Gotz et al., *supra*).

Figure 18 is a photograph of a bacterial plate assay for staphyloytic activity of 
milk expressed in mouse mammary tissue. Shown in the top row of the plate, left to 
right, is bacterially derived lysostaphin 500, 250, 125, and 62 ng/ml. Middle row, left 
to right: skim milk from the BLG-Lys transgenic mouse high expression line (1.3 mg 
Gln^{125,232}-lysostaphin per ml of milk) diluted 1:200, 1:400, 1:800, or 1:1600. Shown 
in the bottom row, left to right: skim milk from a non-transgenic mouse diluted 1:200, 
1:400, 1:800, or 1:1600.

Figure 19 is a Northern blot of RNA from various tissues of a transgenic mouse 
showing almost complete mammary specificity of lysostaphin expression.

**Description of the Sequence Listing**

SEQ ID NO: 1 is the sequence of the naturally-occurring lysostaphin gene of 
*S. simulans* (Recsei et al., *supra*) (Figure 11).

SEQ ID NO: 2 is the sequence of the naturally-occurring lysostaphin protein. 
The sequence presented is of the preproprotein (Figure 12).

SEQ ID NO: 3 is the sequence of an inventive altered lysostaphin gene (Figure 
13).

SEQ ID NO: 4 is the β-lytic protease gene from *Achromobacter lyticus* (Figure 
14).

SEQ ID NO: 5 is a second sequence of a naturally-occurring lysostaphin 
protein (Heinrich et al., *Mol. Gen. Genetic.*, 209:563-569, 1987) (Figure 15).
SEQ ID NO: 6 is a third sequence of the naturally-occurring lysostaphin protein (Thumm and Gotz et al., Molecular Microbiology, 23:1251-1265, 1997) (Figures 16 and 17).

Definitions

"Altered gene": An “altered” gene, as used herein, is identical to a naturally-occurring gene except that the nucleotide sequence of the altered gene has been modified with respect to that of the naturally-occurring gene through the addition, deletion, substitution, or inversion, of one or more nucleotide residues. Preferred altered genes are those in which the coding sequence of a microbial anti-staphylococcal agent is operatively linked with mammalian expression sequences. Particularly preferred altered genes are those in which at least a portion of the microbial sequence (sufficient to encode a protein with anti-staphylococcal activity) is linked to sequences that direct the secretion of the protein from mammalian cells. Such preferred altered genes may also include sequence modifications that remove (or add) sites for post-transcriptional modifications that would otherwise occur in the mammalian cells. As will be clear to those of ordinary skill in the art, in the context of “altered gene”, a “gene” includes expression signals as well as coding sequence.

"Gene": Generally speaking, a “gene”, as used herein, is a single transcription unit. However, as will be clear from context and is understood in the art, the term can be used in more than one way. The “gene” for a particular protein always includes the sequence that actually encode the protein. A “gene” may also include regulatory sequences such as sites recognized by transcriptional regulators, or responsible for transcriptional termination. A “gene” may also include intronic sequences and/or splicing signals.

"Microbial host": The term “microbial host” is any self-replicating host of microscopic size that encodes within its nucleic acid genome, an anti-microbial agent. As used herein, “microbial host” can also refer to plants and fungi that encode within their nucleic acid genomes an antimicrobial agent useful in the present invention.
“Naturally-occurring”: The term “naturally-occurring” is sometimes used herein to describe microbial genes encoding agents with anti-staphylococcal activity and is intended to refer to the form of the gene (i.e., the gene sequence) that is present in nature, i.e., in the microbial host in which the gene is found. Any self-replicating entity that contains nucleic acid and is found in nature can be a “microbial host” for the purposes of this definition. Moreover, although it is not generally so used in common parlance, the term “microbial host”, as used herein, may refer to a plant host.

“Operatively linked”: The term “operatively linked” is used herein to refer to nucleic acid sequences that are associated with one another in such a way that they are operative with respect to one another. For example, a promoter is operatively linked to a gene coding sequence when it is associated with that sequence in a manner that allows it to direct transcription of that sequence. Typically, operative linkage involves covalent attachment via a 3'-5' phosphodiester bond. Those of ordinary skill in the art will appreciate that the precise nature of the linkage may vary depending on the nature of the sequences being associated. For example, whereas a promoter is typically required to be 5' (upstream) to gene coding sequences to be operative, other transcriptional regulatory sequences (e.g., enhancers) can very often exert effects from upstream, downstream, or within coding sequences, frequently regardless of orientation.

“Recombinant”: The term “recombinant”, as used herein, refers to a nucleic acid or protein that is produced using the established techniques of recombinant DNA technology (i.e., digestion with restriction endonuclease, ligation, site-specific DNA mutation, polymerase chain reaction, etc.). A recombinant protein is one that is produced from a gene that was made thereof, or from replicative progeny thereof.

“Regulatory sequence”: A regulatory sequence is a region of DNA that, when altered or deleted, has an effect on the expression level of the gene with which it is operationally linked. Typically, regulatory sequences are regions of DNA that are recognized (i.e., bound by) protein factors that participate in the regulation of gene expression.
Detailed Description of the Preferred Embodiments

Altered anti-staphylococcal genes

As mentioned above, the present invention provides altered versions of microbial genes that encode agents with anti-microbial activity, the versions having been modified so that they direct expression of active protein in mammalian tissues or cells.

Those of ordinary skill in the art will appreciate that a significant number of microbial proteins, naturally found in any number of microbial hosts, are known to have anti-microbial activity. In principle, the genes encoding any such proteins could be altered in accordance with the present invention. Preferred genes include those encoding anti-staphylococcal activity, for example, \( \beta \)-lytic protease, lysostaphin, \(-\)lytic protease, lyt-M, at1AEL-1, zooA. Other preferred anti-microbial peptides or proteins whose genes could be utilized include lysozyme, nisin, muramidases, glucoamminidases, and colicins. (see, for example Shockman and Barrett, Proc. Natl. Acad. Sci. U. S.A., 51:414-421, 1964; Yamada et al., J. Bacteriol., 178:1565-1571, 1996). Particularly preferred are genes encoding bacteriocins, which are peptide antibiotics that are produced by bacteria and are effective against even closely related species but do not have significant deleterious effects on the species that produces them or on eukaryotic cells. One particularly preferred bacteriocin gene is the lysostaphin gene.

ALTERED LYSOSTAPHIN GENES

concentrations of recombinant lysostaphin against \textit{S. aureus} are less than 100 ng per ml in culture media and less than 2 \mu g per ml in milk, \cite{Bramley1990, Oldham1991}. This low concentration requirement makes lysostaphin an attractive candidate for the prevention and treatment of mastitis, because one requirement of the present invention is that the protein be expressed and secreted at sufficient concentrations \textit{in vivo} to kill \textit{S. aureus}.

The gene encoding lysostaphin is naturally found on a large plasmid in \textit{S. simulans}, and encodes a preproenzyme that is processed extracellularly to a mature form, which is active (Figure 1). Several allelic variations of this gene have been identified that are apparently found in nature \cite{Heinrich1992, Recsei1991, Thumm1991, supra}. The sequence of mature lysostaphin identified by Heinrich, \cite{Heinrich1992} differs from the sequence identified by Recsei, \cite{Recsei1991} by one amino acid, whereas preprolysostaphin has multiple differences. Furthermore, the preprolysostaphin sequence identified by Thumm and Gotz \cite{Thumm1991} differs from the preprolysostaphin sequence identified by both Recsei \cite{Recsei1991} and Heinrich \cite{Heinrich1992}. According to Thumm and Gotz \cite{Thumm1991}, preprolysostaphin is 493 amino acids having a signal peptide of 36 amino acids, a propeptide of 211 amino acids and a mature lysostaphin protein of 246 amino acids.

In the present application the term “mature form” refers to a lysostaphin protein which has had the propeptide cleaved off. It should be noted, however, that “active forms” of lysostaphin are not limited to the mature form; other unprocessed forms of lysostaphin also have activity. In particular, preprolysostaphin and prolysostaphin. Prolysostaphin is bioactive, but mature lysostaphin is 4.5 times more bioactive than prolysostaphin \cite{Thumm1991}. Variations of lysostaphin that can be modified to be expressed in an active form in mammalian cells fall within the scope of the presently claimed invention.

In order to prepare an altered lysostaphin gene according to the present invention, the naturally-occurring lysostaphin gene sequence must be modified to allow
for expression of active lysostaphin protein in mammalian cells. As will be appreciated by those of ordinary skill in the art, expression of bacterial proteins in mammalian cells is often not trivial. Typically, the bacterial coding sequence must be operatively linked to a mammalian, or at least a eukaryotic, promoter and a eukaryotic translation initiation sequence. Although it is often not required that every nucleotide of coding sequence be preserved, or that the coding sequence initiate and terminate at precisely the same points as it does in its natural host system (fusion proteins and modest deletions are usually tolerated), it is essential that the coding sequence to be employed be operatively linked to expression signals that are effective in the cells into which the altered gene is to be introduced.

A large number of different eukaryotic, and particularly mammalian, expression signals are known in the art and include promoters, transcriptional regulatory sequences (often provided in conjunction with the promoter with which they are naturally associated or with a promoter with which they have previously been experimentally associated), transcriptional termination signals, splicing signals, translation initiation signals, post-translational processing signals, and secretory signals (see, for example, Current Protocols 16.0 - 16.21.9). Those of ordinary skill in the art will appreciate that not every one of such signals must be employed in an altered gene of the present invention. It is generally preferred to include eukaryotic (preferably mammalian) transcription and translation initiation signals; other sequences may be employed as necessary or desirable. Various other modifications may also be made.

Promoters that may be employed include constitutive promoters, inducible promoters, universal promoters (i.e., active in substantially all cell types), and/or tissue specific promoters. Those of ordinary skill in the art will appreciate that the precise application of the inventive altered gene will determine which category of promoter is more desirable. For example, if expression is desirably limited to a particular tissue, a tissue-specific promoter is employed; if expression is desirably limited to times when certain environmental conditions are present, an inducible promoter responsive to those environmental conditions is employed. Particular promoters are also selected on the basis of their ability to direct higher or lower levels of transcription.
As mentioned above and discussed more fully below, in certain preferred embodiments of the present invention, an altered lysostaphin gene is to be expressed in mammary tissue. If the altered gene is to be introduced only into mammary cells, a tissue-specific promoter is not required. Preferred promoters for use in such circumstances include, but are not limited to, Cytomegalovirus, (CMV), Rous Sarcoma Virus (RSV) and human elongation factor 1 (EF-1) α subunit. Particularly preferred is the CMV promoter. Of course, a tissue-specific promoter may nonetheless be employed. Known mammary-specific promoters include, for example, β-lactoglobulin, α-lactalbumen, caseins and whey acidic protein. Particularly preferred is the β-lactoglobulin promoter.

The Kozak sequence is well established to be the eukaryotic translation initiation sequence and is the preferred sequence to be introduced into altered genes of the present invention.

Williamson and colleagues have previously reported that operative linkage of the entire lysostaphin gene to the human cytomegalovirus promoter and the Kozak initiation sequence is sufficient to direct expression of lysostaphin in COS-7 cells, but active enzyme was not secreted from the cells (Williamson et al., *Appl. Environ. Microbiol.*, 60:771-776, 1994). The low level of activity detected by William et al. (*supra*) (less than 1 ng/ml) is likely due either to release from lysed cells and a small amount of protein that escapes glycosylation in the *in vitro* system.

As described in Example 1 and Figure 2, we have prepared an altered version of the lysostaphin gene that directs production and secretion of active lysostaphin from mammalian cells. Our first attempt at producing an active, secreted lysostaphin in mammalian cells utilized a construct, pCMV-Lys, in which the coding sequence for mature lysostaphin was operatively linked to the cytomegalovirus promoter and the bovine growth hormone polyadenylation signal. This construct, like that described by Williamson et al., (*supra*) was sufficient to produce lysostaphin in mammalian cells, but did not produce active secreted protein (Figure 3).

In an effort to correct this problem, we produced a second construct, pCMV-hGH-Lys, that included a mammalian signal peptide to direct secretion of the
lysostaphin protein from the cell. Those of ordinary skill in the art will appreciate that
any of a number of different signal peptides could have been used including, but not
limited to, β-lactoglobulin, caseins, erythropoietin, and insulin, so long as they were
linked in-frame to the lysostaphin coding sequence. We elected to use the human
growth hormone signal peptide, because expression and secretion of the entire human
growth hormone gene had previously been demonstrated in the ruminant mammary
gland (Kerr et al., Anim. Biotechnol. 7:33-45, 1996). Moreover, the human growth
hormone signal peptide had previously been used to direct the secretion of engineered
proteins from Chinese hamster ovary cells (Peceu et al., Gene, 97:253-258, 1991).

In analyzing the inactive lysostaphin produced from our second construct, we
noted that it had a molecular weight of approximately 33 Kd, somewhat larger than the
lysostaphin standard that migrated at 28 Kd (Figure 4). We hypothesized that post-
translational processing events, in particular glycosylation events, might be disrupting
the activity of the lysostaphin produced in mammalian cells. Other post-translational
processing events that might affect biological activity include methylation, disulfide
bond formation, acetylation, phosphorylation and sialylation. As those of ordinary skill
in the art will appreciate, bacterial proteins are not normally glycosylated. However,
when such proteins are expressed in a mammalian system, there is the possibility that
the mammalian cell will recognize putative glycosylation steps within the sequence of
the bacterial protein, and will add glycosyl groups that may alter the activity of the
protein. Glycosylation of lysostaphin during secretion inactivates the lysostaphin
protein. Consequently, it may be desirable to modify the potential glycosylation sites
to prevent deactivation of the lysostaphin protein by glycosylation during secretion.

We scanned the lysostaphin protein sequence for possible glycosylation sites
that might be recognized in a mammalian expression system. We identified two
instances of the sequence Asn-X-(Ser/Thr), which can be recognized by mammalian N-
linked glycosylation machinery. We confirmed that exposure of the protein to N-
glycosidase F, which removes N-linked glycosyl groups, reduced the apparent
molecular weight of the protein to that of the lysostaphin standard (Figure 4).
In light of these findings, we prepared new constructs in which we had modified one or both of the N-linked glycosylation sites by substituting Gln for Asn (Figure 2). Those of ordinary skill in the art will recognize that any of a variety of other approaches could be used to disrupt a potential N-linked glycosylation site, but substitution is generally preferred over addition or deletion of residues. Conservative substitutions (i.e., substitutions with amino acids of comparable chemical characteristics) are particularly preferred. For the purposes of conservative substitution, the non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, glycine, proline, phenylalanine, tryptophan and methionine. The polar (hydrophilic), neutral amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

We found that removal of both glycosylation sites resulted in production of an active, secreted lysostaphin from mammalian cells (see Examples 1 and 5). We note that this observation of active lysostaphin secreted from mammalian cells is the first such demonstration. In fact, prior work evidences the difficulty of achieving active secreted protein. In particular, WO 96/35793, reports detection of very large amounts (100 to 250 ng/ml/24 hours) of lysostaphin protein in cell extracts, but little or no activity of that material. Accordingly, an “altered lysostaphin gene” of the present invention is a lysostaphin gene whose sequence has been modified as compared with that of naturally-occurring lysostaphin (SEQ ID NO:3) in that lysostaphin coding sequence sufficient to encode at least mature lysostaphin has been (i) operatively linked to mammalian expression signals sufficient to direct expression of the gene product in mammalian cells; (ii) operatively linked to a mammalian signal peptide such that the expressed gene product is secreted from the mammalian cells in which it is produced, and, preferably, (iii) modified such that at least one, and preferably both, of the Asn-X-(Ser/Thr) N-linked glycosylation sites is disrupted. Alternatively, it may be desirable to eliminate the signal peptide to permit intracellular accumulation of the antimicrobial protein.
As mentioned above, the lysostaphin coding sequence that is useful in the production of altered lysostaphin genes according to the present invention is not limited to the mature lysostaphin sequence; the preprolysostaphin and prolystaphin sequences have also been shown to produce active proteins, although expression of the immature form of lysostaphin is substantially less than that of the mature form. Moreover, as will be appreciated by those of ordinary skill in the art, various changes to the precise lysostaphin amino acid sequence can readily be made without interfering with (and sometimes promoting, as seen in the glycosylation site examples) lysostaphin activity. So long as the lysostaphin amino acid sequence does not differ so extensively from that presented as SEQ ID NO:2 that activity is lost, the sequence may be used in accordance with the present invention. Those of ordinary skill in the art are well familiar with techniques for modifying amino acid sequences (see, for example, Sambrook, J. et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, N.Y., incorporated herein by reference), and may employ any known technique, including those described herein, to assay the proteins produced from genes containing such modifications in order to determine whether such genes encode functional proteins as required by the present invention. Altered genes that direct expression and secretion of an active lysostaphin protein with one or more sequence differences from naturally-occurring lysostaphin (SEQ ID NO:1) or from the particular altered lysostaphin described herein (SEQ ID NO:3) are considered to be "functional equivalents" of the altered lysostaphin described herein, and are within the scope of the present invention.

Additional modifications to the lysostaphin gene that fall within the scope of the present invention include, for example, nucleotide substitutions that more accurately reflect eukaryotic codon usage without altering the amino acid sequence of the encoded protein (see, for example, (Sambrook et al., supra). Such changes are expected to enhance the efficiency of translation and the amount of protein being produced. Another modification involves removal or disruption of a potential polyadenylation signal near the 3' end of the lysostaphin gene.
ALTERED β-LYTIC PROTEASE GENES

Another preferred bacterial gene for use in the production of altered genes according to the present invention is the β-lytic protease gene (SEQ ID NO:4) from *Achromobacter lyticus* (Li et al., *J. Bacteriol.*, 172:6506-6511, 1990). β-lytic protease exhibits potent bacteriolytic activity on *Micrococcus lysodeikticus* and *S. aureus*. It is approximately 25-fold more potent than lysostaphin on heat killed *S. aureus*, and approximately 40-fold more potent than lysostaphin on viable *S. aureus* (Li et al., *J. Biochem.* (Tokyo), 122: 772-778, 1997).

An altered β-lytic protease gene according to the present invention is produced, as was the case with the lysostaphin gene, by operatively linking β-lytic protease coding sequence with (i) a mammalian promoter; (ii) a mammalian translation initiation sequence; and (iii) a mammalian signal peptide. Additional modifications may also be made.
OTHER ALTERED GENES

Any of a variety of other genes encoding agents with anti-microbial activity may also be employed in accordance with the present invention. As discussed above, a variety of different microbial anti-staphylococcal agents are known. Any gene encoding such an agent may be modified as described herein to produce an altered gene of the present invention. Useful genes may be isolated from any natural source, including bacteria, fungi, plants, and other microbes.

These other anti-staphylococcal genes are modified to produce altered genes of the present invention through operative linkage with (i) a mammalian promoter; (ii) a mammalian translation initiation sequence; and (iii) a mammalian signal peptide. Additional modifications may also be made. For example, some such genes may have introns, or sequences that are recognized as introns, that are inappropriately spliced in a mammalian system. Such inappropriate splicing events can be identified, for example, by isolating mRNA from a mammalian cell transfected with a version of the gene that has been modified to include the mammalian promoter, translation initiation sequence, and signal peptide. Inappropriate splicing may be corrected by alteration of inappropriate splice sites, or removal of intronic sequences. However, it is often desirable to maintain (or introduce) at least one intron in an altered gene, as intron-containing genes are often more efficiently expressed in mammalian systems (see, for example, Wall and Seidel, Theriogenology, 38:337-357).

Also, the mammalian signal peptide might not be properly cleaved from the protein produced upon expression of a modified gene containing a mammalian promoter, translation initiation sequence, and signal peptide in a mammalian cell. Inappropriate signal peptide cleavage may be identified by immunopurification of the expressed protein, which is then analyzed by polyacrylamide gel electrophoresis and/or N-terminal sequencing. Problems with signal peptide cleavage can generally be corrected through selection of a different signal peptide, such as one from one of the major milk proteins.
Additionally, as discussed above, modifications may be made to introduce mammalian codons without changing protein sequence, to remove or disrupt any putative glycosylation sites and/or polyadenylation signals, etc.

Finally, those of ordinary skill in the art will recognize that the principles taught by the present invention are readily applicable to genes encoding proteins or peptides with anti-microbial (including anti-viral) activity other than, or in addition to, anti-staphylococcal activity. For example, as mentioned above, *Staphylococcus aureus* accounts for up to only 30% of intra-mammary infections (Nickerson et al., *J. Dairy Sci.*, 78:1607-1618, 1995). It will be clear to one skilled in the art that the other 70% of intra-mammary infections are due to other pathogens and therefore any protein with anti-bacterial activity that would combat the offensive pathogen could be delivered to the mammary gland for treatment of mastitis. Furthermore, multiple genes could be delivered to the mammary gland simultaneously (see further discussion below).

*Introduction of altered genes into mammalian expression systems:*

The altered anti-microbial genes of the present invention may be introduced into mammalian cells or tissues in order to treat or prevent infection of those tissues. *In vitro* transfection methods that introduce DNA into mammalian cells in culture are well known in the art and include calcium phosphate transfection, DEAE-dextran transfection, electroporation, and liposome-mediated transfection.

In the present invention, it is preferred that the method of protein expression utilize methods that transfer DNA into living cells *in vivo*. In certain embodiments, the genes are delivered by somatic cell engineering, or gene therapy. In such circumstances, the genes are not delivered to the animal’s offspring, and are often (unless retroviral delivery systems are employed) only transiently expressed in the cells to which they are delivered.

A variety of systems are available for delivering altered genes to somatic cells, either systemically or locally, in accordance with the present invention (see, for example, Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates, New York, V. 1&2, 1996 and Kerr et al., *Anim. Biotechnol.*, 7:33-45,
1996). Such systems include, but are not limited to, high-pressure jet injection, liposome-based delivery systems, and viral delivery systems, including both retroviral and standard viral systems.

The mammalian cells and tissues into which the altered genes of the present invention are to be produced include any mammalian cells or tissues. Preferred cells and tissues are within ruminants such as cows, sheep, and goats, but also include humans. Also, although mammary tissue is one particularly preferred tissue for expression (see below), any tissue that is susceptible to or that has microbial infection, is a desirable expression site according to the present invention.

Notwithstanding the foregoing, expression in mammary tissue is a particularly preferred aspect of the present invention. Thus, in preferred embodiments of the invention, the delivery system is selected, in combination with the gene modifications, to ensure that the altered gene is expressed in mammary tissue. In one particularly preferred embodiment, an altered anti-staphylococcal gene is delivered locally to mammary epithelial cells via the teat canal. This route of intramammary infusion administration has the greatest chance of transfecting the epithelial cells lining the teat or teat duct, which are a prime target for attachment and invasion by staphylococcal species and therefore are also an important target for the production of anti-microbial proteins. Alternatively, in another preferred embodiment, delivery of plasmid DNA into lactating sheep mammary parenchyma can be achieved by high-pressure jet-injection. This method achieves transfection of cells within the narrow path of the injectate (Kerr et al., Anim. Biotechnol., 7:33-45, 1996).

In other preferred embodiments of the present invention, viral vector approaches are utilized to achieve transient transfection of mammary epithelial cells with inventive altered genes. Viral vector approaches include retro- (Kay et al., *Science*, 262:117-119, 1993), adeno- (Smith et al., *Nat. Genet.*, 5:397-402, 1993), and adeno-associated viruses (Flotte, *J. Bioenerg. Biomembr.*, 25:37-42, 1993). Retrovirus infection results in integration of the viral nucleic acid sequence into the host cell DNA, causing permanent transfection of that cell. Retroviruses can only infect dividing cells, but have been shown to be capable of transfecting the caprine mammary gland during a period of hormone-induced mammmogenesis (Archer et al., *Proc. Natl. Acad. Sci. U.S.A.*, 91:6804-6844, 1994).

In a particular preferred embodiment, an adenovirus vector is used to deliver altered anti-staphylococcal genes to bovine mammary epithelial cells. The adenoviral-based method of gene delivery has several advantages over retroviral-based gene delivery in that transfection efficiency is higher and it can infect non-dividing cells. New adenoviral vectors have also been developed that limit the host antiviral immune response, which is common to adenoviral transfection. A strong cellular immune response can greatly reduce the persistency of adenoviral-mediated gene expression and precludes repeated administration of the same vector (Ilan et al., *Proc. Natl. Acad. Sci. U.S.A.*, 94:2587-2592, 1997; Chen et al., *Proc. Natl. Acad. Sci. U.S.A.*, 94:1645-1650, 1997; Smith et al., *supra*). We have demonstrated that an adenoviral vector systems can be successfully employed for delivery of genes to the ruminant mammary (Plaut et al., *J. Dairy Sci.*, 80, Suppl. 1, 155 (Abstract), 1997) (see Example 2). Direct administration of adenovirus containing the β-galactosidase gene to the teat of a goat resulted in intense blue staining of the entire lining of the teat canal (see Figure 7). Mammary tissues were also infected. This finding is readily generalizable to the inventive altered genes, which may therefore also be delivered to ruminant mammary cells through adenoviral transfection (see Example 3).

Those of ordinary skill in the art will appreciate that it will sometimes be desirable to express more than one inventive altered gene simultaneously in the same mammalian cells or tissue. With this multi-gene approach, not only is the spectrum of
the bactericidal activity improved, but the likelihood of bacterial resistance
development is substantially diminished.

**Transgenic animals**

The altered genes of the present invention may also be introduced into
mammalian cells through transfer into mammalian germ line cells and subsequent
production of transgenic animals. Established methods for such germ line transfer
include, but are not limited to, micro injection of DNA into one-cell embryos (Gordon
engineered embryonic stem-cells into blastocysts (Hooper et al., *Nature*, 326:292-295,
1987; Kuehn et al., *Nature*, 326:295-298, 1987), and the transfer of nuclei from
Germ genetically engineered cells to oocytes (Schnieke et al., *Science*, 278:2130-2133,
1997) result in a permanent change in the animal’s genome and the genomes of its
offspring.

Germ cell engineering has become wholly routine in the area of transgenic mice
(Gordon et al., *Biotechnology*, 5:1183-1187, 1987), and has also been broadly applied
et al., *Biotechnology*, 9:830-834, 1991), goats (Ebert et al., *Biotechnology*, 9: 835-838,
1991), and cattle (Krimpenfort et al., *Biotechnology*, 9:844-847, 1991). To give but
one relevant example, Gordon et al., (*Biotechnology, supra*) have created transgenic
mice that produced human tissue plasminogen activator in transgenic mouse milk.
Any of the techniques described in these references, or otherwise known in the art, may
be employed to create transgenic animals in which an altered gene of the present
invention has been stably introduced into their genome. Such transgenic animals are
useful not only as staphylococcus-resistant creatures, but as bioreactors for the
production of anti-staphylococcal agents for use in the treatment of others.

**Peptide antibiotics**
Peptide antibiotics are widespread in nature, being found in plants, animals, and prokaryotes. Animal antibacterial proteins include lysozyme, lactoferrin, and a class of antimicrobial compounds known as defensins. Lysozyme is a muramidase to which Gram negative and some Gram positive microorganisms, such as S. aureus, show varying degrees of resistance (for reviews, see Reiter et al., “Protective Proteins in Milk-Biological Significance and Exploitation”, *International Dairy Federation Bulletin* #191. IDF, Square Vergote 41, 1040 - Brussels, Belgium; Maga and Murray, *J. Dairy Sci.*, 78:2645-2652, 1995). It is normally present in human milk at approximately 100 μg per ml and in ruminant milk at less than 1 μg per ml, yet the role lysozyme may play in the prevention of mastitis is presently unknown. However, lactoferrin, which acts as an antimicrobial through its iron-chelating activity (Reiter et al., *supra*), does protect the non-lactating mammary gland from infection by *E. coli*, although this inhibition is lost at the time of calving (Bramley, *J. Dairy Res.*, 43:205-211, 1976). This is exemplified by the fact that the concentration of lactoferrin in normal milk, which is about 200-300 μg/ml, is unable to prevent infection, and the concentration of lactoferrin in milk in infected cows, which is in excess of 1mg/ml, is unable to cure infection.

Furthermore, the defensins, produced in neutrophils, macrophages, and epithelial cells lining mucosal surfaces (Kagan et al., *Toxicology*, 87:131-149, 1994), also have antibacterial action resulting from their ability to form pores in susceptible cellular membranes. One particular defensin, bovine tracheal antimicrobial peptide (TAP) has antibacterial activity in vitro against *E. coli* and *S. aureus*, with minimum inhibitory concentrations (Diamond et al., *Proc. Natl. Acad. Sci. U.S.A.*, 88:3952-3956, 1991; Yarus et al., *Proc. Natl. Acad. Sci. U.S.A.* 93:14118-14121, 1996) and would therefore be a likely candidate for use in the present invention. Analogous peptides to the defensins, called magainins, have been isolated from amphibian skin and are being evaluated as topical antibiotics for human medicine (Jacob and Zasloff, *Ciba Found. Symp.* 186:197-216 discussion 216-223, 1994). So far, the activity of these cationic peptides in milk is compromised, presumably through binding to phosphorylated caseins or inserting into the milk fat globule membrane.
Examples

The present invention can be further understood through consideration of the following non-limiting Examples.

Example 1

Genetic engineering of the lysostaphin gene

A. Construction of new lysostaphin expression plasmids

In an attempt to increase production and secretion of lysostaphin, four new expression constructs were prepared (Figure 2). All four constructs were made by inserting modified lysostaphin genes into the polly linker of the 5.4 Kb eukaryotic expression vector, pcDNA3 (Invitrogen). The vector contains the CMV promoter and the bovine GH polyadenylation signal, with an intervening polly linker.

All four lysostaphin constructs were generated by a PCR-based technique in which the 5' primer included a 5' Not I restriction site and the 3' primer included a 3' Apa I site. The primers were positioned such that only the coding region and the TGA stop codon of the mature portion of the lysostaphin gene were amplified. We used pCMLEM (Simmonds et al., Appl. Environ. Microbiol., 62:4536-4541, 1996) as the lysostaphin template, and the resulting Not I - Lysostaphin - Apa I amplicons were cloned between the Not I and Apa I sites in the pcDNA3 polly linker. The nucleotide sequences of all PCR-generated fragments were confirmed with an automated cycle-sequencing technique at the University of Vermont molecular diagnostics laboratory.

The expression plasmid pCMV-Lys was constructed by inserting a short linker sequence 5' to the mature lysostaphin sequence, between the Bam HI and Not I sites of the pcDNA3 polly linker. The short sequence was prepared from two custom 13 base oligonucleotide (Gibco/BRL), and resulted in the addition of a Kozak sequence and a start codon (ATG) to the lysostaphin gene. These features, which are required for efficient translation initiation, encode the insertion of an additional N-terminal amino acid (methionine) to the lysostaphin protein. This engineered protein does not contain a signal peptide and thus would not be transferred to the golgi apparatus for glycosylation and secretion.
The expression plasmid pCMV-hGH-Lys was constructed by inserting the human growth hormone (hGH) intron-containing signal peptide coding region, 5' to the mature lysostaphin sequence. This eukaryotic signal peptide was chosen to enhance the secretion of lysostaphin from the cells. We have previously had satisfactory experience with the expression of the entire hGH gene in the ruminant mammary gland (Kerr et al., *Anim. Biotechnol.*, 7:33-45, 1996), and it has been used by others to direct the secretion of engineered proteins (Pecceu et al., *Gene*, 97:253-258, 1991). The coding region of the hGH signal peptide included the 5' untranslated region and the first intron of the hGH gene. The intronic sequence was included, as there is good evidence that introns increase expression of foreign proteins (Wall and Seidel, Jr., *Theriogenology*, 38, 337-357, 1992). The modified hGH signal peptide was obtained from a collaborator (Dr. K. Wells, GEML-ARS-USDA, Beltsville, MD). The resulting hGH-lysostaphin sequence codes for the amino acids of the entire hGH signal peptide immediately followed by the entire mature form of lysostaphin. The sequence of this construct was confirmed by DNA sequencing.

The expression plasmids pCMV-hGH-Lys-ΔGly2 and pCMV-hGH-Lys-ΔGly1-ΔGly2 were subsequently prepared. A PCR strategy was used to remove glycosylation sites from the mature lysostaphin gene and generate pCMV-hGH-Lys-ΔGly2 and pCMV-hGH-Lys-ΔGly1-ΔGly2. pCMV-hGH-Lys-ΔGly2 removes one of two potential N-linked glycosylation sites within mature lysostaphin. The final construct, pCMV-hGH-Lys-ΔGly1-ΔGly2, was designed to encode a lysostaphin protein in which both N-linked glycosylation sites (Asn-X-Ser/Thr) have been removed by mutation of the site’s Asn codons to Gln codons (Figure 2). Bacterial proteins are not normally glycosylated, but when expressed in a eukaryotic system, any Asn-Xxx-Ser/Thr sequence of amino acids in a protein has the potential for N-linked glycosylation. The plasmids pCMV-hGH-Lys-ΔGly2 and pCMV-hGH-Lys-ΔGly1-ΔGly2, were constructed in a similar fashion to pCMV-hGH-Lys. However, the 3' primer for generating the lysostaphin amplicon contained nucleic acid substitutions that resulted in a change from AAT to CAG at the codon for amino acid number 232 of the mature lysostaphin protein. This causes an asparagine to glutamine change in the encoded
protein, and thus destruction of the potential glycosylation site. We chose to convert Asn to Gln based on the similar structure and characteristics of their side groups. The plasmid pCMV-hGH-Lys-ΔGly1-ΔGly2 was similarly constructed using a synthetic 5' primer. The Asn to Gln strategy was recently reported as being successful in preventing the glycosylation of a bacterial enzyme that was engineered to be expressed on the cell surface of eukaryotic cells (Marais et al., Nat. Biotechnol. 15:1373-1377, 1997). Importantly, these authors reported considerable enzymatic activity of the modified protein was maintained, even with three Asn to Gln mutations.

B. Evaluation of lysostaphin expression plasmid in vitro

Lysostaphin expression from the four new constructs was evaluated following their transfection into COS-7 cells. The cells were transfected in six-well culture plates, with a CaPO4 precipitation technique (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, N.Y., 1989, incorporated herein by reference). Following exposure to the plasmid precipitate, cells were washed and then incubated with 1 ml DMEM containing 10% FBS for 48 hours. Media was then collected, cleared by centrifugation, and stored (-20°C). Cell extracts were obtained by freeze/thaw disruption of the cell monolayer with 0.5 ml phosphate buffered saline (PBS). Transfection efficiency was monitored visually by co-transfection with a green fluorescent protein (GFP) expression plasmid. The plasmid, pCMV-GFP, was constructed by inserting the GFP encoding fragment from pEGFP-N1 (Clontech) into pcDNA3. Plasmid DNA used in transfections contained a 9:1 mixture of the test plasmid and pCMV-GFP. Consistently high (>50%) transfection efficiencies were obtained (Figure 7F).

Cell extracts from COS-7 cells transfected with the signal peptide devoid construct, pCMV-Lys, exhibited bacteriolytic activity using plate assay technique (Figure 3s and 5). Specifically, conditioned media or cell extracts were lyophilized and resuspended with the original volume (1X), 0.5 volume (2X), or 0.25 volume (4X) of H2O. Lysostaphin standards were prepared in media. Samples or standards (15 ul) were then applied to an LB agar plate freshly streaked with S. aureus and incubated 16
hours, 37°C. For the plate assay, aliquots of the cell extract or conditioned media were spotted onto culture plates that had been freshly streaked with *S. aureus* (strain M60). Following an overnight incubation, clear lytic zones were observed. We estimated the lysostaphin concentration to be ≈50 ng/ml by comparison with standard preparations containing a commercial lysostaphin preparation (Sigma L-7386). No activity was detected in media, presumably because the lysostaphin gene lacked a signal peptide. No activity was detected in media or cell extracts from cells transfected with a control plasmid, pCMV-hGH. Thus, the COS-7 cells are capable of producing lysostaphin, and the lysostaphin appears to be non-toxic.

Lysostaphin bioactivity was not detected using the *S. aureus* plate assay, in either media or cell extracts from COS-7 cells transfected with pCMV-hGH-Lys. However, substantial lysostaphin immunoreactivity was observed by Western blot assay of media, but not extracts, of cells transfected with pCMV-hGH-Lys (Figure 6, lane 4). Proteins were separated on a 12% polyacrylamide-SDS gel, transferred to nitrocellulose membranes and probed with a rabbit anti-lysostaphin polyclonal antibody. Bound antibodies were detected with an alkaline phosphatase-linked second antibody and BCIP/NBT substrate. The band representing lysostaphin migrated with an apparent molecular weight of ≈33 Kd, somewhat larger than the lysostaphin standard that migrated at ≈28 Kd. Media samples were estimated to contain ≈200 ng/ml of immunoreactive lysostaphin. To determine if the larger molecular weight of the engineered protein was due to N-linked glycosylation, samples were deglycosylated by overnight incubation with N-glycosidase-F (Boehringer-Mannheim). A clear reduction in the apparent molecular weight of the expressed protein, compared to that of the lysostaphin standard, was observed (Figure 4, lane 5). Thus, addition of the hGH signal peptide region to pCMV-Lys directed the secretion of relatively large quantities of a glycosylated inactivated lysostaphin protein by COS-7 cells. The 26 amino acid signal peptide, which has a predicted molecular weight of 2.7 Kd, was apparently cleaved, as the deglycosylated protein had a similar molecular weight to the lysostaphin standard.
Transfection with the pCMV-hGH-Lys-ΔGly2 construct did not result in the desired increase in activity or size reduction of COS-7 produced lysostaphin. The media, but not cell extracts, obtained from these transfections contained similar levels of similar sized immunoreactive lysostaphin as those resulting from pCMV-hGH-Lys transfections (Figure 6, lane 6).

Transfection of the Eucaryotic cell line, COS-7, with the pCMV-hGH-Lys-ΔGly1-ΔGly2 construct, that encodes a lysostaphin protein in which both N-linked glycosylation sites have been removed reveals bioactive lysostaphin in the culture media but not in the cell extracts (see Figure 5). Strong, yet indirect evidence for secretion of the protein, rather than cell lysis and release into media, is found by comparison of results obtained from the signal peptide devoid construct pCMV-Lys to the new construct containing the hGH signal peptide, pCMV-hGH-Lys. Without the signal peptide, lysostaphin accumulates within the cells such that cell extract, but not media, cause bacterial cell lysis. This media likely does contain some lysostaphin resulting from cell lysis, but the concentration is below the detection limits of our assay. However, with the hGHI signal peptide and the deglycosylation construct, bioactive lysostaphin is detected only in the media, not in the cell extract. Presumably the cell extract contains an amount of bioactive Lysostaphin that is below detection. No bioactivity is observed from cells transfected with the construct containing the hGH signal peptide and the unmodified lysostaphin gene.

Example 2:

Adenovirus mediated expression of β-galactosidase

A. Propagation of AvILacZ4

The plasmid AvILacZ4 (Genetic Therapy Inc; Bethesda, MD) is a replication deficient, recombinant, human type 5 adenovirus that contains the gene for nuclear targeted β-galactosidase (LacZ) (Smith et al., supra). The E3 region of this adenovirus has been deleted and the β-galactosidase gene replaces the E1a region rendering the virus replication incompetent. Viral stocks were prepared using the 293 packaging cell line (ATCC #CRL-1573). This cell line is a stable transfectant that produces the Ad 5
E1a transcription factor and thus complements the E1a deletion in the recombinant virus. Briefly, confluent 293 cells were infected with the virus and 36 hours later the propagated virus particles recovered by 5 cycles of freeze/thawing. A cleared lysate was obtained by low speed centrifugation, and a purified preparation was obtained following two rounds of CsCl density-gradient ultracentrifugation. The CsCl was removed by extensive dialysis against sterile 10 mM Tris pH 7.4, 1 mM MgCl₂, 10% glycerol. Viral stocks were stored at -70°C. Titres of the viral stocks were determined by plaque assay using 293 cells.

B. Infection of a ruminant cell line with Av1LacZ4

To confirm integrity of our viral stocks and to ensure that the human Ad5 would infect ruminant cells, a bovine mammary epithelial cell line, BME-UV clone E-T2 (Zavizion et al., In Vitro Cell Dev. Biol. Anim. 32:138-148, 1996) was exposed to Av1LacZ4 (10 pfu/cell). After 48 hours, the cells were fixed and stained for β-galactosidase activity using the X-Gal reagent. The infection was successful (Figure 7E).

C. Infection of the goat mammary gland in vivo

Goats were exposed to Av1LacZ4 to evaluate the ability of the human adenovirus to infect the ruminant mammary gland in vivo. Two mature, virgin, and three multiparous goats, which had been non-lactating for three months, were infused with the LacZ containing adenovirus. One teat of each goat was infused with 1 ml of a solution (10 mM Tris pH 7.4, 1 mM MgCl₂, 10% glycerol) containing Av1LacZ4 (1.9 x 10¹⁰ pfu/ml). The contralateral teat acted as a control being infused with vehicle. A similar set of infusions was administered 48 hours later but the concentration of virus was reduced to 0.6 pfu/ml. The animals were euthanized 24 hours later.

Teat tissue and mammary tissue samples adjoining the base of the teat were fixed in 2% paraformaldehyde - 0.20% glutaraldehyde and processed for detection of β-galactosidase activity (Furth et al., Molecular Biotechnology, 4:121-127, 1995). Intense blue staining of the entire lining of the teat canal was observed (Figure 7A). Histological sections revealed that the infection was limited to the luminal cell layer (Figure 7C). Mammary tissues were also infected (Figure 7B).
Primary cultures of mammary tissues were prepared by collagenase digestion and plating on plastic culture dishes. After 24 hours incubation in DMEM containing 10% FBS in a 5% CO2 atmosphere, the cultures were fixed and stained with X-Gal. Infected mammary epithelial cells were observed (Figure 7D). There was no staining visible in tissues or cells from vehicle infused glands.

D. Characterization of adenoviral-mediated transfection of the goat mammary gland

In order to continue to explore adenoviral transfection of the goat mammary gland, the β-galactosidase-containing adenovirus Av1LacZ4 is used. These studies are conducted with two, non-lactating multiparous goats treated similarly to the experiment described above. First, the dose response characteristics using a single infusion of adenovirus is explored. Goats are infected with a single, 1 ml infusions of 1.0 x 10^{11}, 1.0 x 10^{10}, 1.0 x 10^{9} and 1.0 x 10^{8} pfu/ml. Contralateral glands receive vehicle alone. These doses are based upon previous results. Mammary secretions are obtained prior to, and at, 24 hours and 48 hours post-infusion. The goats are euthanized 48 hours post-infusion. Evaluation of the infections includes monitoring animal health (temperature, respiration, ruminination, and post-mortem evaluation) and determining SCC and the presence of bacterial infection.

Transfection is evaluated by staining teat and mammary tissues with X-gal reagent and subsequently evaluating them grossly and microscopically. Histopathology is also evaluated. Infusions of 1.9 x 10^{10} and 0.6 x 10^{10} pfu/ml are administered 72 hours and 24 hours prior to euthanasia, respectively. A minor inflammatory response may develop as evidenced by fluid accumulation in the gland and an elevation in somatic cell count. Rectal temperatures are monitored. Secretions are examined for bacterial contamination. This characterization allows determination of a lower dose of adenovirus that will ameliorate these symptoms, and yet still provide adequate transfection.
E. Adenoviral-based transfection of the goat mammary gland with an engineered lysostaphin construct.

Adenoviral-based transfection of the goat mammary gland in vivo has been undertaken as described for the Av1LacZ4 infections. Each of two multiparous non-lactating goats were infected in one gland by intramammary teat infusion with the lysostaphin-containing adenovirus. The contralateral gland was infused with the LacZ-containing adenovirus. The goats were euthanized 48 hours post-infusion. Mammary secretions were collected prior to infusion, and at 24 hours and 48 hours post-infusion. Secretions and tissues from the glands were processed as previously described with additional measurements for lysostaphin production and activity as follows.

Secretions from the glands and extracts prepared from tissue fragments were assayed for immunoreactive lysostaphin using Western blot and an ELISA assays (Kerr et al., Nat. Biotechnology (January, 2001) 19(1):66-70). Prior to performing the assays, sample infranatants were prepared by two sequential centrifugation steps (15 min, 12,000g, 4°C) in which the fluid between the fat layer and pelletable protein and debris was harvested. All secretions were normalized based upon total protein content, determined by a modification of the Lowry method (Nerurkar et al., “Quantification of selected intracellular and secreted hydrolyses of macro phages.” In Manual of Macrophage Methodology. H.B. Herscowitz, et al., eds. (New York: Marcel Dekker, Inc.) pp. 229-246, 1981). Recovery of standard lysostaphin added to samples prior to processing was determined. At 48 hours post-infusion, the secretions collected from the two glands infused with the lysostaphin adenovirus contained 860 ng/ml and 1100 ng/ml, respectively, of lysostaphin. No lysostaphin was detected in the secretions from the contralateral glands infused with the lacZ-adenovirus.

Lysostaphin production is also evaluated in tissue sections processed for immunohisto-chemistry using our rabbit polyclonal antibody to lysostaphin.

Immunohistochemical techniques are currently available. Briefly, formalin fixed tissue is embedded in paraffin, and sectioned (6μm) by the UVM histology core facility. Slides are then deparaffinized and rehydrated. Endogenous peroxidases are blocked by a 10 min incubation with 0.3% hydrogen peroxide in methanol. Non-specific protein
binding is blocked with a 30 min incubation in 10% normal goat serum in 1% BSA-PBS. Sections are incubated for 60 min with 10μg/ml of rabbit polyclonal antibody generated against lysostaphin. Bound antibody is detected with biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) subsequently coupled to streptavidin-peroxidase. The chromogen, amino ethyl carbazole (AEC) and the substrate (0.6% peroxide) are next added to the sections, allowing the development of a red color (Zymed Laboratories, San Francisco, CA). Negative controls are incubated with the primary antibody in the presence of a 100 fold excess of a lysostaphin.

Methods for adenoviral-based transfection of the lactating goat mammary gland are also available. Briefly, experiments are conducted, similar to those described above, during the sixth week of established lactation. Kids are used to initiate and maintain lactation, but are replaced by hand milking during the viral infusions. Milk is removed from glands immediately prior to adenoviral infusion. Oxytocin is administered to ensure let-down. One gland is infused with AvlLacZ4, the other with the lysostaphin containing adenovirus. Initial dose response experiments, conducted with two goats / dose, are undertaken to evaluate transfection during lactation. These experiments are 48 hours in duration. Subsequent longer duration experiments are conducted with a dose determined from previous experiments.

Example 3:

Adenovirus mediated expression of lysostaphin

A. Construction of Adenoviruses containing lysostaphin genes

GTI supplied start up quantities of an E3 region deletion mutant (AD5-dl327) of the AD5 adenovirus and the shuttle plasmid pAvS6 (Smith et. al., supra) that was used to construct the recombinant adenoviruses carrying the lysostaphin gene. The Not I-Kpn I fragment of the shuttle plasmid contains the inverted terminal repeat and encapsidation signal from the left end of AD5-dl327, the RSV promoter, a multi cloning region for insertion of the gene of interest, the SV40 Poly (A+) signal, and
Ad5 sequences from nucleotide 3328 to 6246 that serve as a homologous recombination region.

Two shuttle plasmids were constructed. One, named pAvS6-preprolys, was constructed by inserting the 1.5 Kb modified lysostaphin gene from pCMLEEM (Williamson et al., 1994) into the pAvS6 shuttle vector. This modified lysostaphin gene contained a Kozak region linked to the preprolysostaphin gene. The other, called pAvS6-hGH-Lys-ΔGLY1-ΔGLY2, contained the human growth hormone signal peptide linked to the modified lysostaphin construct, which was obtained from pCMV-hGH-Lys-ΔGLY1-ΔGLY2.

The shuttle plasmids pAvS6-preprolys and pAvS6-hGH-Lys-ΔGLY1-ΔGLY2 were independently used to generate two recombinant adenoviruses: Ad-preprolys and Ad- hGH-Lys-ΔGLY1-ΔGLY2, respectively. The recombinant viruses were constructed by co-transfection of the linearized shuttle plasmids with the ClaI fragment of Ad5-dl327 into 293 cells. Resulting plaques were purified. Insertion of the lysostaphin genes into the viral genomes was confirmed by polymerase chain reaction.

B. Evaluation of lysostaphin production by COS-7 cells infected with Ad-preprolys

Near confluent cultures of COS-7 cells were exposed to a cleared cell lysate from 293 cells that had been infected with Ad-preprolys to evaluate lysostaphin production. Samples of culture media and cell extracts were prepared from the infected COS-7 cells 48 hours after infection. Lysostaphin production was evaluated by an SDS-PAGE - Western blotting technique using a rabbit polyclonal antibody to lysostaphin (Figure 3). The antibody was prepared for us by R. Sargent Inc. (Ramona, CA) using affinity purified lysostaphin (Sigma L-4402). Samples (50μl) were denatured by boiling in the presence of a β-mercaptoethanol-containing loading buffer and electrophoresed through a 1.5 mm thick, 12 % polyacrylamide gel for 4 hours (Protean II apparatus; Bio-Rad). Proteins were then transferred to nitrocellulose for immunodetection. Bound anti-lysostaphin antibody was detected with an alkaline phosphatase-linked second antibody (Sigma) and BCIP/NBT reagent (Bio-Rad). Cell
extract from Ad-preprolys infected COS-7 cells contained a detectable quantity of immunoreactive lysostaphin that migrated with an apparent molecular weight of ≈ 90 Kd (Figure 3, lane 10). This molecular mass is very similar to that previously observed by Williamson et al. (supra) (1994) following introduction of a similar lysostaphin construct using a plasmid based calcium phosphate transfection protocol. The protein is most likely preprolysostaphin. Mature lysostaphin migrates with an apparent MW of ≈28 Kd (Figure 3, lanes 7, 8). The lysostaphin derived from Ad-preprolys infected COS-7 cells was apparently not secreted, as it was not detectable in the corresponding media sample (Figure 3, lane 11). No bioactivity was detected in media or cell extracts from Ad-preprolys infected COS-7 cells.

C. Evaluation of lysostaphin production by 293 cells infected with Ad- hGH-Lys-ΔGLY1- ΔGLY2

Lysis of S. aureus (M60) by bioactive lysostaphin produced by 293 cells infected with Ad- hGH-Lys-ΔGLY1- ΔGLY2 was evaluated by plate assay. Samples (60 ul) or standards (15 ul) were added to a LB agar plate freshly streaked with S. aureus. Results were evaluated following a 12 hour incubation at 37°C. Lysostaphin standards were prepared in media. The concentrations were 3 ng/ul, 30 ng/ul and 100 ng/ul. Inhibition of S. aureus growth was observed by the standard preparations and by culture media obtained from 293 cell cultures that had been infected with Ad- hGH-Lys-ΔGLY1- ΔGLY2. These results are illustrated in Figure 1.

Example 4:

Production and evaluation of transgenic mice incorporating the lysostaphin gene under control of a mammary specific promoter.

This model allows assessment of the functionality of the transgene when incorporated into the genome of an animal, determination of toxicity of the transgenic protein to the lactating mammary gland, and assessment of the effects of the transgene on milk production. The antibacterial properties of milk from these animals can also be measured. A variety of mammary gland and lactation specific promoter regions
may be used to direct expression of the lysostaphin gene to the lactating mammary gland. These include, but are not limited to, the regulatory sequences of the casein genes, whey acidic protein, and β-lactoglobulin. We chose to use the β-lactoglobulin regulatory sequence.

A. Lysostaphin Expression in Milk

The 4.2 Kb 5'-flanking (promoter) region and the 2.1 Kb of the 3-flanking region of the ovine β-lactoglobulin (BLG) gene (pBJ41) were obtained from Dr. A.J. Clark (Roslin Institute, UK). These components have been used to direct the production of mg/ml concentrations of foreign proteins into the milk of mice (Archibald et al., Proc. Natl. Acad. Sci. USA 87,5178-5182, 1990) and sheep (Wright et al., Biotechnology 9, 830-834, 1991). The 1.4 Kb modified lysostaphin gene containing the hGH signal peptide was excised from pSec-Lys-G1n2 and inserted into pBJ41 between the 5'- and 3'- components of the BLG gene. The entire 7.7 Kb fusion gene (BLG-Sec-Lys-G1n2) was then excised and purified for microinjection. Nine founder transgenic mice were produced in the laboratory of Dr. R.J. Wall (USDA-ARS-GEML; Beltsville, MD) using standard techniques. Five lines of mice have now been established. These mice appear normal, are fertile, and are able to raise offspring. To date, milk has been obtained from F1 mice representing three of the lines. The milk was collected on day 10 of lactation (Maga et al., J. Dairy Sci. 78: 2645-2652, 1995). The milk samples were immediately frozen (-80) and then shipped to our laboratory on dry ice.

Milk was analyzed for lysostaphin immunoreactivity as described for cell culture experiments. Prior to analysis milk samples were diluted (1:10) in PBS containing 0.5% BSA, then defatted by centrifugation (15 min, 4, 10,000g). Western blot analysis of milk from three different BLG-Sec-Lys-G1n2-transgenic mice (#16797, #16796, #16775) revealed a very intense lysostaphin band (Figure 9). The migration distance appears identical to the lysostaphin standard.

Milk from another BLG-Sec-Lys-G1n2-transgenic mouse (#16755) contained substantial staphyloytic bioactivity (Figure 10). The lytic zones that developed from a
dilution series of milk indicated that a 1:1,600 dilution of milk contained an amount of bioactivity equivalent to between 125 ng/ml and 250 ng/ml of lysostaphin standard (Sigma).

B. In vivo lysostaphin activity in mice

The use of transgenesis to direct mammary gland expression of foreign protein in the mouse was first reported in 1987 by Gordon et al. (Biotechnology 5:1183-1187). This technology spread to transgenic pigs (Wall et al., Proc. Natl. Acad. Sci. USA (1991) 88:1696-1700), sheep (Wright et al., Biotechnology (1991) 9:830-834), goats (Ebert et al., Biotechnology (1991) 9:835-838), and cattle (Krimpenfort et al., Biotechnology (1991) 844-847). The present example demonstrates that secreting a modified, biologically active form of lysostaphin in milk protects transgenic mice against S. aureus infection. These results demonstrate that a genetic engineering approach may be an effective strategy for combating mastitis, the single most problematic disease problem in dairy cattle industry.

Modification of the bacterial lysostaphin gene for eukaryotic expression of bioactive Glh\textsuperscript{125,232}.lysostaphin was carried out as described above. Briefly, the Sec-Gln-Lys construct was inserted between the 4.2 Kb 5' -flanking region and the 2.1 Kb 3' flanking region of the ovine \(\beta\)-lactoglobulin gene. The entire 7.7 Kb BLG-lysostaphin (BLG-Lys) fusion gene, was then used to generate transgenic mice. Eight potential founders carrying the BLG-Lys construct were identified by Southern blot analysis. Two of these animals did not transmit their transgene to progeny. Daughters of three other founders expressed lysostaphin in their milk at a very low concentration (<20\(\mu\)g/ml) and therefore these lines were not further evaluated. Offspring founder 16535 produced lysostaphin at 75 \(\mu\)g/ml of milk and was designated as the low expressing line. The BLG-Lys transgene integrated at two loci in the genome of founder 16654 segregated independently in his progeny. The segregation of one of the sites resulted in the generation of a sub line expressing 150 \(\mu\)g/ml of milk which was designated the medium expressing line. The other site produced a sub-line expressing approximately 1 mg/ml of milk and was designated as the high expressing line.
Milk from these mice contains substantial staphyloolytic activity, as detected by a bacterial plate assay. Although the eukaryotically produced Gln125,232-lysostaphin appears to be 5- to 10- fold less potent than bacterially derived lysostaphin, as shown below, it is potent enough to inhibit *S. aureus* infection of mouse mammary tissue *in vivo*. The difference in biological activity was demonstrated by comparison of lytic zones in a lawn of *S. aureus* resulting from application of bacterial lysostaphin standards or dilutions of a milk sample from a high expressing line transgenic mouse (Figure 18). The milk sample contained 1.3 mg/ml immunoreactive lysostaphin, yet the lytic zone developed from a 1:1600 dilution of this sample, which would contain approximately 800 ng/ml, was similar to that produced by a solution containing 125 ng/ml bacterial lysostaphin. In contrast, milk from non-transgenic mice does not contain staphyloolytic activity.

Northern blot analysis of RNA from various tissues of a transgenic mouse revealed almost complete mammary specificity of lysostaphin expression (Figure 19). Correct spicing of nascent Gln125,232-lysostaphin mRNA by eukaryotic cells was confirmed by cloning and sequencing an amplification product resulting from RT-PCR of RNA obtained from a stably transfected cell line. The primers were located in the plasmid sequence outside of the Sec-Gln125,232-Lys construct.

Susceptibility to mastitis following intramammary infection was evaluated with a murine model previously developed to demonstrate the efficacy of lysostaphin as a mastitis therapeutic (Bramley et al., *Res. Vet. Sci.*, (1990) 49:120-121). Experimental mastitis was produced by intramammary inoculation as described by Bramley et al. (*Res. Vet. Sci.*, (1990) 49:120-121) and Chandler, R.L. (*J. Med. Microbiol.* (1970) 3:273-282). In the experimental model, two abdominal mammary glands of mice were inoculated with *S. aureus* (10^4^ cfu/50 μl PBS) on the tenth day of lactation. To put this dose into perspective, cows are often experimentally challenged with less than 1000 cfu (Oldman and Daley, *J. Dairy Sci.* (1991) 74;4175-4182; Watson, D.L., *Res. Vet. Sci.* (1992) 53:346-353). Pups were removed and inoculum delivered to anesthetized mice via the teat canal with a 100 μl Hamilton syringe fitted with a 34 g blunt needle. This dose of bacteria is sufficient to cause severe infection within 24 hours, at which
point the mice are euthanized and mammary homogenates prepared. Mice were maintained on an analgesic (buprenorphine) during the incubation period. Viable *S. aureus* in the homogenate were determined by plating out a dilution series on blood agar plates, incubating for 24 hours, then enumerating colonies. Colony morphology and hemolytic clearing were used as indicators of *S. aureus*.

The dose of *S. aureus* administered was sufficient to cause active intramammary infection in all infused glands of non-transgenic mice, see Table 1 below. In contrast, glands of the high expressing line BLG-Lys transgenic mice were completely resistant to infection, as were approximately 40% of glands from the medium and low expression lines. Further, 17 of 22 control glands were classified as severely infected, based on *S. aureus* recovery. These glands had obvious visible signs of trauma, such as bloody, serous exudate surrounding the mammary glands. In marked contrast, the glands of transgenic mice never exhibited visual signs of infection, even in those glands from the low and medium expressing lines that contained viable *S. aureus*. In Table 1, the degree of resistance to infection was related to the amount of lysostaphin in the glands.

**Table 1.** Infection status of mouse mammary glands 24 hours after intramammary challenge with *S. aureus*. Glands were infused on day 10 of lactation with *S. aureus* (10⁶ cfu/50ml/gland). Infection status is based on number of *S. aureus* (cfu) recovered from each gland 24 hours post-infusion (Wilson et al., J. Dairy Sci. (1997) 80:2592-2598). Each abdominal mammary gland (L4, R4) was homogenized in 2 ml PBS.
<table>
<thead>
<tr>
<th>Line</th>
<th>Glands Infused</th>
<th>Glands Infected</th>
<th>Infection Status (cfu/gland)</th>
<th>Lysostaphin in mammary gland (ug/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Severe ($&gt;10^6$)</td>
<td>Moderate ($10^5$ to $10^6$)</td>
</tr>
<tr>
<td>Non-transgenic</td>
<td>22</td>
<td>22</td>
<td>17</td>
<td>4</td>
</tr>
<tr>
<td>BLG-Lys Low</td>
<td>8</td>
<td>5</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>BLG-Lys Medium</td>
<td>6</td>
<td>3</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>BLG-Lys High</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

To summarize, this example demonstrates that transgenic production of lysostaphin by lactating mammary gland will confer substantial resistance to staphylococcal mastitis. Furthermore, the staphyloytic enzyme does not appear to affect mammary integrity, milk quality, or ability to produce fermented dairy products. Mice from the highest expressing line were completely resistant to experimental challenge, while mice from the medium and low expressing lines had clearly enhanced resistance. Viable *S. aureus* were recovered from approximately 60% of challenged glands from the low and medium expressing transgenic mice. However, none of these glands were severely or visibly infected, as were 77% of non-transgenic glands.

**Example 5:**

**Transgenic Ruminants**

The present invention provides transgenic dairy cows containing a modified lysostaphin gene, although the cost and duration of such an endeavor necessitates
preliminary experiments using the much less expensive, and more rapid, transgenic mouse model.

A. Production of Non-Rodent Transgenic Animals

Procedures for the production of transgenic non-rodent mammals and other animals have been discussed by others (see Houdebine and Chourrout, supra; Pursel et al., *Science* 244:1281, 1989; and Simms et al., *Bio/Technology*, 6:179, 1988). Such procedures can be applied to an altered gene of the present invention to produce transgenic dairy cows expressing lysostaphin (see Krimpenfort et al., *Biotechnology*, 9:844-847, 1991, incorporated herein by reference). If expression is desirably limited to mammary tissues, a mammary-specific promoter may be employed.

Other Embodiments

One of ordinary skill in the art will readily recognize that the foregoing represents merely a detailed description of certain preferred embodiments of the present invention. Various modifications and alterations of the genes and uses thereof described above can readily be achieved using expertise available in the art, and are within the scope of the following claims.

All references cited herein are hereby incorporated by reference.

We claim:
1. A nucleic acid comprising a modified gene encoding an anti-microbial protein wherein the coding sequence is from the natural host, but has been modified to allow expression of the active form.

2. The gene of claim 1 wherein the modified gene is operatively linked to at least one mammalian regulatory sequence.

3. The gene of claim 1 wherein the modified gene contains mutations that eliminate one or more glycosylation sites.

4. A modified gene comprising a gene encoding lysostaphin, wherein the lysostaphin gene has been modified to allow expression of the active form of lysostaphin.

5. The gene of claim 4 wherein the modified gene is operatively linked to at least one mammalian regulatory sequence.

6. The gene of claim 4 wherein the modified gene is operatively linked to at least one mammalian regulatory sequence and contains mutations that eliminate one or more glycosylation sites.

7. The gene of claim 4 wherein the modified gene is operatively linked to at least one mammalian regulatory sequence and contains mutations that eliminate both glycosylation sites

8. The gene of claim 4 wherein the gene encoding lysostaphin comprises preprolysostaphin.
9. The gene of claim 4 wherein the gene encoding lysostaphin comprises prolysostaphin.

10. The gene of claim 4 wherein the gene encoding lysostaphin comprises mature lysostaphin.

11. A nucleic acid comprising a gene encoding lysostaphin that is biologically active when expressed in mammalian cells.

12. The gene of claim 11 wherein the gene encoding lysostaphin is modified as compared with SEQ ID NO: 3, modifications selected from the group consisting of:
   at least one mammalian regulatory sequence operatively linked to the lysostaphin coding region; and
   removal of at least one glycosylation site.

13. The gene of claim 11 wherein the gene encoding lysostaphin is modified as in SEQ ID NO: 3 which comprises:
   a eukaryotic start codon;
   the Kozak expression start site consensus sequence;
   a eukaryotic promoter
   a eukaryotic secretion signal; and
   the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.

14. The gene of claim 11 wherein the gene encoding lysostaphin is modified as in SEQ ID NO: 3 which comprises:
   a eukaryotic start codon;
   the Kozak expression start site consensus sequence;
   a eukaryotic promoter; and
the lysostaphin gene from which two glycosylation sites in the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.

15. The gene of claim 11,12,13 or 14 wherein the gene encoding lysostaphin comprises preprolysostaphin.

16. The gene of claim 11,12,13 or 14 wherein the gene encoding lysostaphin comprises prolysostaphin.

17. The gene of claim 11,12,13 or 14 wherein the gene encoding lysostaphin comprises mature lysostaphin.

18. A method for treating staphylococcal infection in a mammalian system, the method comprising expressing in the cells of the system, a modified gene encoding lysostaphin.

19. The method of claim 18 wherein expressing the gene involves expressing a copy of the gene which is integrated into the cellular genome.

20. The method of claim 18 wherein the gene encoding lysostaphin is modified as compared to SEQ ID NO: 3 so that at least one mammalian regulatory sequence is operatively linked to the lysostaphin coding region and at least one glycosylation site is removed.

21. The method of claim 18 wherein the gene encoding lysostaphin is modified as in SEQ ID NO: 3 so that at least one mammalian regulatory sequence is operatively linked to the lysostaphin coding region and both glycosylation sites are removed.
22. The method of claim 18 herein the gene encoding lysostaphin is modified as in
SEQ ID NO: 3 which comprises:
   a eukaryotic start codon;
   the Kozak expression start site consensus sequence;
   a eukaryotic promoter
   a eukaryotic secretion signal; and
   the lysostaphin gene from which two glycosylation sites in the
lysostaphin gene from which two glycosylation sites in the lysostaphin gene were
removed.

23. The gene of claim 21 wherein the gene encoding lysostaphin is modified as in
SEQ ID NO: 3 which comprises:
   a eukaryotic start codon;
   the Kozak expression start site consensus sequence;
   a eukaryotic promoter; and
   the lysostaphin gene from which two glycosylation sites in the
lysostaphin gene from which two glycosylation sites in the lysostaphin gene were
removed.

24. The method of claim 18, 22, or 23 wherein the gene encoding lysostaphin
comprises preprolysostaphin.

25. The method of claim 18, 22, or 23 wherein the gene encoding lysostaphin
comprises prolysostaphin.

26. The method of claim 18, 22, or 23 wherein the gene encoding lysostaphin
comprises mature lysostaphin.

27. A transgenic mammalian animal which comprises a transgene encoding
lysostaphin.
28. The transgenic mammalian animal of claim 27 wherein the lysostaphin transgene has been modified for expression of an active form in mammalian cells.

29. The transgenic mammalian animal of claim 27 wherein the transgene encoding lysostaphin is modified as in SEQ ID NO: 3 which comprises:
   a eukaryotic start codon;
   the Kozak expression start site consensus sequence;
   a eukaryotic promoter
   a eukaryotic secretion signal; and
   the lysostaphin gene from which two glycosylation sites in the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.

30. The gene of claim 27 wherein the gene encoding lysostaphin is modified as in SEQ ID NO: 3 which comprises:
   a eukaryotic start codon;
   the Kozak expression start site consensus sequence;
   a eukaryotic promoter; and
   the lysostaphin gene from which two glycosylation sites in the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.

31. The transgenic mammalian animal of claim 27 wherein the modified transgene is inserted into the bovine β-lactoglobulin expression cassette which comprises:
   4.2 kilobase pairs of the 5'-regulatory region of the bovine β-lactoglobulin gene;
   exons 5, 6, and 7 of the bovine β-lactoglobulin gene; and
   2.0 kilobases of 3'-untranslated region of the bovine β-lactoglobulin gene.
32. A transgenic mammalian animal which comprises a transgene encoding an anti-microbial protein.

33. The transgenic mammalian animal of claim 32 wherein the anti-microbial transgene has been modified for expression of an active form in mammalian cells.

34. The transgenic mammalian animal of claim 32 wherein the anti-microbial transgene encoding lysostaphin is modified to comprise:
   a eukaryotic start codon;
   the Kozak expression start site consensus sequence;
   a eukaryotic promoter
   a eukaryotic secretion signal; and
   the lysostaphin gene from which two glycosylation sites in the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.

35. The gene of claim 32 wherein the gene encoding the anti-microbial is modified to comprise:
   a eukaryotic start codon;
   the Kozak expression start site consensus sequence;
   a eukaryotic promoter; and
   the lysostaphin gene from which two glycosylation sites in the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.

36. The transgenic mammalian animal of claim 32 wherein the modified transgene is inserted into the bovine β-lactoglobulin expression cassette which comprises:
   4.2 kilobase pairs of the 5'-regulatory region of the bovine β-lactoglobulin gene; exons 5, 6, and 7 of the bovine β-lactoglobulin gene; and 2.0 kilobases of 3'-untranslated region of the bovine β-lactoglobulin gene.
Figure 1
TCCACC\text{\textsc{at}}GG (Kozak site)

\text{Pre-peptide} \quad \text{Pro-peptide} \quad \text{Mature lysostaphin}

\text{pCMLEM} (Williamson et al. 1994)

GCCACC\text{\textsc{at}}GG (Kozak site)

\text{pCMV-LYS}

\text{hGH signal peptide} \quad \text{Mature lysostaphin}

\text{pCMV-hGH-Lys}

\text{Gln-Lys-Ser} \quad \text{Asn-Lys-Ser} \quad \text{tga}

\text{pCMV-hGH-Lys-\text{\textDelta}Gly2}

\text{hGH signal peptide} \quad \text{Mature lysostaphin}

\text{pCMV-hGH-Lys-\text{\textDelta}Gly1-\text{\textDelta}Gly2}

\textbf{Figure 2}
<table>
<thead>
<tr>
<th>Plasmid</th>
<th>GH</th>
<th>Lys</th>
<th>GH</th>
<th>Lys</th>
<th>Lys</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reaction buffers</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>N-Glycosidase-F</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Kd</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 4
Figure 5
Figure 10

Lysostaphin (ng/ml)

Dilutions of Transgenic Milk

Dilutions of Control Milk
Figure 11

A. ORIGIN

1 ccggacacttc tgaatgttaa gtttgcgaaa ttcacaaaaa aaacccactct tcttaaatatt
61 gctcctattt attttaacac aatacagttg aataacaaaa tctttaaggtg caatattttga
121 tgtggctttgt gttttccacc aaaaattcac aatattattt accttttttct tcttttattaa
181 aagttcagtt aataaaataa atgcgctgtt caataactca ataataaatc agggaggatt
241 aagtttggag aaaaaaatag aacaatattt tccgagaccc ttgcttattg gactgagttac
301 attggcttta gcaatcactg ttttgaggg gattcacaata gaaacactg tttttgaaaa
361 aagttataag gtggttcccc aaaaaagtttt gtaagttgag aacctttaaa cccagtttga
421 aatatacgcct qaagtagag aataacacac ccttacaaaaa tccagtaagga aataaactgg aagtagagc
481 tttcaaaactt cccgtagaaaa atacagctga agtagagcct ctaaaaggtt ccgtagaaaa
541 tacagctggaagtgagacgtt ccaagctctg gtagtaaag aagctgtaag tagagacgtt
601 aaagccccta gtagaaataa caagctgaaat aagccctggt ttccaaatatag
661 aacagtcttcg aagagctcga cccagacact ttcagcaca aaggtttgaata attcaaaaaa
721 aggataggtt tacgggtcctt atccatagg tataaatggc ggtatgacact acggagttga
781 ttttttbattg aatattgcaa ccacagttta atcgatattc aagcgaaaaa tagttgagcc
841 tgggttgagtt aatctcggag gaggtaatca aataggtctt attgaattag atggaggtcga
901 tagacactgg tatatgcatc taagtaataa taattgttaaa gtagggatt atgtcaaaagc
961 tgtgcaacata atcggttggtt cggagcagc tttgtttcct atccagaccc aatttacattt
1021 ccaaaagaatt gtaggttcttt ttcccccaata aatgtcgtgc ctcttcttaaa
1081 gacagccgagg atgagtcgag cctgggttgcc atggccacca ccgagtttga acgggagttga
1141 aacaaacaaa tatgcacac tatataataa cagatcagct agctctcacc ctaaatacaga
1201 tataataacca aagacgacgtt gttcagttgg aagctatgctg cagtttgag cttttaaaagc
1261 aggtcacaac atccattagat atgaaggtat ggtaaaggac ggtcgatggtt ggttaggttta
1321 tacaggttaac agttgcccaca gtattctttg cctgtagtaa acatggttaa aatcttcactaa
1381 tctcttaggt tgtttttggg gaaataataa tgtagcgggc ttttttataa cttatagattgat
1441 aattagacga aataaaatttt tttttctttct cctaaagtgtt aagttt

B. BASE COUNT

1 gctcgaaccttc atgaacacttc agcagcataag tttgaataatt acaaaaaggg ataggtttac
61 ggtccccctttt attggagttt ataatgctggt gttcaggttggtt tttcttgatt
121 atggaacacca gctgtaaactc tatttcagac ggaattataag ttgagaagtttg tttgattagat
181 taccggaggt ttaacccatt acgtttttat gaatttacagtg gtagtttgta atcaattagat
241 atgcataacca gttttataatat ctttaaagaat gggattatgg tccaaactgtc tcaaatatta
301 gttgctttgtt gaagcacttgga ttatctcaca gcactcactc attacgattt aagatggttt
361 aatcattttt caatccacac gttcagaagt ccacattccct tcttaaaaggt cccagagatatt
421 gggaaaacagc gttgctactgc atccttcaac gcgatacttg ttgagagact ttttaaaggt
481 ggtcgacttta aataacagttt gttaggtcgtt ttctcactc ttcagatattt aataaatagta
541 accgaagttgctt ctttagatgaa cttgcagcagc ctagattgtc ataataagat cttacacat
601 cttttagttgac aagttcagtt aataacacac ccttacaaaaa tccagtaagga aataaactgg aagtagagc
661 ggcccaccagta cttgttctttg cttgtaagac tttgaataatt ctaacattcatt ctttaggtttt
721 cttttgggaaa ctttttaagtg a
Figure 12

"NKKTNNYYTRPLAIGLSTFALSIVYGQMEFHASESKKXDV"

SKKVAEVTSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETS

SKKVNAEVTSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETS

SKALVQNRTALFATHEHSAQWMNNLYKKGYGYGYPYPLGINGGMKGYGDFFMNIGTPVKAISWVIEAGWSYGGGNYQIGLINDVG

LYQAQWAHSLSKYNYVKGDYVKAGQIIGISWGSTGYSTAPHLHFCEMVSNFSNSTAQDMPF

FLKSAGYKGAGGTVTPFTNWTGKTYKTLYKSESASFTPWIIITRTTGPFRSMPQS

GVLKAGQTIHYDEVMKQDGHVVGYTAGNSQRYILPVRITWXSTNTLGVWGTIK"
Figure 14

A. ORIGIN

1 tgcgtgcctg cctcctacctg ttcatacgctg ccacgcgccc ggcggcgctt cgcagcgcga
61 tcgccgacccg tgtgaacgcg atgtgagasc ggcgcgttcgg caagcgcgctg tagggtgcctg
121 attgtgaagct ggcgtcgacg acagacgtgcgg ggcgcgtgtgcg agacgcgcg ggcgcggtaa
181 taagcgtgcag gatgcgcgggc gcgcgatagc gcgaacgcgctg tgtggtgttgt gcgcgatgcgg
241 cgctcgcccgc gtcgggtgccg ggcgcgtgacg gtcgcgcgctg gttcgcgagct ccacgcgcagtgc
301 cttctctctgc ggacgcgttcg gacacagcggt ctcacgctag tccacgagtgc gaccgcgcgtgc
361 tgcgcgttgcg cgacgcgttcg ccgcagcgca ggcgcgaggc ctcagcgcgc cgcgcgtgcgg
421 tlgtgcgggt agtacacgcct gcacgcgctgg ttcgtgcttc gcacgcgcgtgc cgcgcgtgcgg
481 gcgcgtgacg gcagcgcgctg acgcggcgcct gcgcgacgcct gcgcgcgacgcct gcgcgcgacgcct
541 agccgagctg tgcgtgctgc ggcgcggcgc ggcgcggcgc ggcgcggcgc ggcgcggcgc
601 cgcacgagcttc gtcgcggttc cgacggttcg cgcgcgttgcg ccgcgcgttgcg cgcgcgttgcg
661 tgcgcgtgtgg gcgcgcgcgcg cgcgcggttc gcgcgcgttgcg gcgcgcgttgcg gcgcgcgttgcg
721 gcgcgttgccgc gcgcgcgcgcg gcgcgcgttgcg gcgcgcgttgcg gcgcgcgttgcg gcgcgcgttgcg
781 gcgcgcgacgc gcgcgaggttc gcgcgttgtgc gcgcgttgtgc gcgcgttgtgc gcgcgttgtgc
841 acgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
901 tgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
961 gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
1021 gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
1081 ttgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
1141 tacgtcgacgc gcggtcgcgcg gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
1201 tacgtcgacgc gcggtcgcgcg gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
1261 cgccacgcgag ttcgctgcgcg gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
1321 cgccacgcgag ttcgctgcgcg gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
1381 tacgtcgacgc gcggtcgcgcg gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
1441 tgacgtcgcg gcgcgtgtct gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
1501 gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc gcgcgcgcgcgc
Figure 17

"MKKTNNYYTRPLAIGLSTFALASIVYGQIQTASEKSNMDV
SKKVAEVETSKAPVENTAEVESEKAPVNTAENETAEVESEKAPVES
NTAEVENTASKAPVENTAEVESEKAPVNTAENETAEVESEKAPVES
SKAPVENTAEVESEKAPVNTAENETAEVESEKAPVES
NTAEVENTASKAPVENTAEVESEKAPVNTAENETAEVESEKAPVES
NLQINGGMHYGVDFMNIGTPVAISSGKIVEAGWSNYGGNNQIGLIENDGVHRQWYM
LSKYNYVGDYVKAGQIIIGWSGTGYSTAPHLHFQRVMSFSNSTAQDPMPFLKSAGY
KAAGGTVPITPNHTNWGTNKHYITLKYSEASFTPTNDITTRTGGPRSMPSGVLKAAGQTIH
YDEVMKQDGHVVVGYTGNSGQRILPVRTWNKSTNTLGVLWGTIK"
Figure 19

1 ug total RNA

1 2 3 4 5 6 7 8 9 10

Mammary gland Mammary gland Brain Lung Heart Spleen Muscle Kidney Non-mammary mammary gland
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/52 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBL, MEDLINE, EMBASE, WPI Data, PAJ, CHEM ABS Data, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>KERR DAVID E ET AL: &quot;Lysostaphin expression in mammmary glands confers protection against staphylococcal infection in transgenic mice.&quot; NATURE BIOTECHNOLOGY, vol. 19, no. 1, January 2001 (2001-01), pages 66-70, XP002246729 ISSN: 1087-0156 page 66, right-hand column, last paragraph - page 69, right-hand column, paragraph 2; figure 1; table 1 same citations</td>
</tr>
<tr>
<td>Y</td>
<td>same citations</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier document but published on or after the international filing date
  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority date claimed

*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Date of the actual completion of the international search: 7 July 2003

Date of mailing of the international search report: 23/07/2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 051 epo nl, Fax. (+31-70) 340-3016

Authorized officer
Steffen, P
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearable (Continuation of item 1 of first sheet)

This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
   Although claims 18-26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. □ Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. □ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

□ The additional search fees were accompanied by the applicant's protest.

□ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)